You are here: Industry Insights > Alzheimer disease

News List

Late-Life Cognitive Activity May Delay Dementia drugs
July 15, 2021
A cognitively active lifestyle in old age may delay the onset of dementia in Alzheimer disease (AD) by as much as five years, according to a study published online July 14 in Neurology.
Medicare Mulls Coverage for Controversial Drug for Alzheimer Disease drugs
July 14, 2021
Medicare launched a formal process on Monday that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer disease drug with a high price tag and unproven benefits that have prompted widespread controversy.
FDA Head Asks for Investigation Into Alzheimer Disease Drug Approval drugs
July 13, 2021
The controversial U.S. Food and Drug Administration approval of the Alzheimer disease drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Janet Woodcock, M.D., has said.
New Rx Instructions Tighten Use of Controversial Alzheimer Disease Drug drugs
July 09, 2021
The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer disease medication Aduhelm that will likely limit its use.
Lilly to Seek FDA Approval for New Drug for Alzheimer Disease drugs
June 28, 2021
Fresh on the heels of the U.S. Food and Drug Administration approval of the controversial Alzheimer disease drug Aduhelm, the maker of a second medicine that works in similar fashion said Thursday it hopes to apply for approval of its medication later .
2007 to 2014 Saw Decrease in U.S. Incidence of Alzheimer Disease drugs
December 19, 2019
From 2007 to 2014, there was a decrease in the diagnosed incidence of Alzheimer disease (AD), according to a study published online in the Journal of the American Geriatrics Society.
Pain Therapeutics refocuses on Alzheimer's after FDA turns down abuse-deterrent opioid painkiller pharmafile
August 08, 2018
The FDA has voted to reject Texas-based Pain Therapeutics’ abuse deterrent opioid painkiller Remoxy (oxycodone), leading the company to consider a strategic restructure and prompting a strong response from its President and CEO.
Alector raises $133m to advance Alzheimer’s disease drugs pharmaceutical-technology
July 30, 2018
Biotechnology firm Alector has raised $133m in a series E financing round to support further development of its clinical programmes and expand its discovery platform.
Focused Ultrasound May Briefly Open Blood-Brain Barrier drugs
July 27, 2018
A new approach to getting drugs through the blood-brain barrier in Alzheimer's patients shows early promise, according to a study published online July 25 in Nature Communications. The research was published to coincide with the annual Alzheimer's Associa